Complement plays a minimal role in Sm-p80-mediated protection against Schistosoma mansoni

Human Vaccines and Immunotherapeutics

Volumn 10, Issue 3, 2014, Pages 640-647

  Karmakar, Souvik ^a   Zhang, Weidong ^a   Ahmad, Gul ^b   Alam, Mayeen U ^a   Winn, Richard ^a   Torben, Workineh ^c   Le, Loc ^a   Tillery, Kory A ^a   Siddiqui, Afzal A ^a  

^a TEXAS TECH UNIVERSITY HEALTH SCIENCES CENTER SCHOOL OF MEDICINE   (United States)

^b PERU STATE COLLEGE   (United States)

^c TULANE NATIONAL PRIMATE RESEARCH CENTER   (United States)

Author keywords

Calpain; complement; Schistosoma; Schistosomiasis; Sm p80; Vaccine

Indexed keywords

COBROTOXIN; COMPLEMENT COMPONENT C3; CYTOKINE; IMMUNOGLOBULIN G1; IMMUNOGLOBULIN G2A; IMMUNOGLOBULIN G2B; IMMUNOGLOBULIN G3; IMMUNOGLOBULIN M; PROTEIN P80; RECOMBINANT PROTEIN; SCHISTOSOMA VACCINE; CALPAIN; PARASITE ANTIGEN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY RESPONSE; ARTICLE; CLINICAL EFFECTIVENESS; CONTROLLED STUDY; CYTOKINE PRODUCTION; DRUG EFFECT; DRUG EFFICACY; FLUORESCENCE ACTIVATED CELL SORTING; GROWTH INHIBITION; IN VITRO STUDY; IN VIVO STUDY; INFECTION PREVENTION; MOUSE; NONHUMAN; OUTCOME ASSESSMENT; PARASITE IDENTIFICATION; PARASITE LOAD; PARASITE VIABILITY; PROTEIN EXPRESSION; SCHISTOSOMA MANSONI; SCHISTOSOMIASIS MANSONI; TH1 CELL; TH17 CELL; TH2 CELL; ANIMAL; C57BL MOUSE; DEFICIENCY; DISEASE MODEL; IMMUNIZATION; IMMUNOLOGY; KNOCKOUT MOUSE; PROCEDURES;

ANIMALS; ANTIGENS, HELMINTH; CALPAIN; COMPLEMENT C3; DISEASE MODELS, ANIMAL; IMMUNIZATION; MICE, INBRED C57BL; MICE, KNOCKOUT; PARASITE LOAD; SCHISTOSOMA MANSONI; SCHISTOSOMIASIS MANSONI;

EID: 84898471164     PISSN: 21645515     EISSN: 2164554X     Source Type: Journal    
DOI: 10.4161/hv.27576     Document Type: Article

References (48)

1. Gryseels B, Polman K, Clerinx J, Kestens L. Human schistosomiasis. Lancet 2006; 368:1106-18; PMID:16997665; http://dx.doi.org/10.1016/S0140-6736(06) 69440-3
2. Gryseels B. Schistosomiasis. Infect Dis Clin North Am 2012; 26:383-97; PMID:22632645; http://dx.doi.org/10.1016/j.idc.2012.03.004
3. Hotez PJ, Fenwick A. Schistosomiasis in Africa: an emerging tragedy in our new global health decade. PLoS Negl Trop Dis 2009; 3:e485; PMID:19787054; http://dx.doi.org/10.1371/journal.pntd.0000485
4. Rollinson D, Knopp S, Levitz S, Stothard JR, Tchuem Tchuenté LA, Garba A, Mohammed KA, Schur N, Person B, Colley DG, et al. Time to set the agenda for schistosomiasis elimination. Acta Trop 2013; 128:423-40; PMID:22580511; http://dx.doi.org/10.1016/j.actatropica.2012.04.013
5. Ross AG, Bartley PB, Sleigh AC, Olds GR, Li Y, Williams GM, McManus DP. Schistosomiasis. N Engl J Med 2002; 346:1212-20; PMID:11961151; http://dx.doi.org/10.1056/NEJMra012396
6. King CH. Parasites and poverty: the case of schistosomiasis. Acta Trop 2010; 113:95-104; PMID:19962954; http://dx.doi.org/10.1016/j.actatropica.2009. 11.012
7. King CH, Olbrych SK, Soon M, Singer ME, Carter J, Colley DG. Utility of repeated praziquantel dosing in the treatment of schistosomiasis in high-risk communities in Africa: a systematic review. PLoS Negl Trop Dis 2011; 5:e1321; PMID:21949893; http://dx.doi.org/10.1371/journal.pntd.0001321
8. Parker M, Allen T. Does mass drug administration for the integrated treatment of neglected tropical diseases really work? Assessing evidence for the control of schistosomiasis and soil-transmitted helminths in Uganda. Health Res Policy Syst 2011; 9:3; PMID:21211001; http://dx.doi.org/10.1186/1478-4505-9-3
9. Prichard RK, Basáñez MG, Boatin BA, McCarthy JS, García HH, Yang GJ, Sripa B, Lustigman S. A research agenda for helminth diseases of humans: intervention for control and elimination. PLoS Negl Trop Dis 2012; 6:e1549; PMID:22545163; http://dx.doi.org/10.1371/journal.pntd.0001549
10. Bergquist NR, Leonardo LR, Mitchell GF. Vaccine-linked chemotherapy: can schistosomiasis control benefit from an integrated approach? Trends Parasitol 2005; 21:112-7; PMID:15734657; http://dx.doi.org/10.1016/j.pt.2005.01.001
11. Bergquist R, Al-Sherbiny M, Barakat R, Olds R. Blueprint for schistosomiasis vaccine development. Acta Trop 2002; 82:183-92; PMID:12020891; http://dx.doi.org/10.1016/S0001-706X(02)00048-7
12. Bergquist R, Utzinger J, McManus DP. Trick or treat: the role of vaccines in integrated schistosomiasis control. PLoS Negl Trop Dis 2008; 2:e244; PMID:18575619; http://dx.doi.org/10.1371/journal.pntd.0000244
13. Karcz SR, Podesta RB, Siddiqui AA, Dekaban GA, Strejan GH, Clarke MW. Molecular cloning and sequence analysis of a calcium-activated neutral protease (calpain) from Schistosoma mansoni. Mol Biochem Parasitol 1991; 49:333-6; PMID:1775175; http://dx.doi.org/10.1016/0166-6851(91)90078-K
14. Andresen K, Tom TD, Strand M. Characterization of cDNA clones encoding a novel calcium-activated neutral proteinase from Schistosoma mansoni. J Biol Chem 1991; 266:15085-90; PMID:1869543
15. Siddiqui AA, Zhou Y, Podesta RB, Karcz SR, Tognon CE, Strejan GH, Dekaban GA, Clarke MW. Characterization of Ca(2+)-dependent neutral protease (calpain) from human blood flukes, Schistosoma mansoni. Biochim Biophys Acta 1993; 1181:37-44; PMID:8457603; http://dx.doi.org/10.1016/0925-4439(93)90087-H
16. Silva EE, Clarke MW, Podesta RB. Characterization of a C3 receptor on the envelope of Schistosoma mansoni. J Immunol 1993; 151:7057-66; PMID:8258710
17. Ahmad G, Zhang W, Torben W, Haskins C, Diggs S, Noor Z, Le L, Siddiqui AA. Prime-boost and recombinant protein vaccination strategies using Sm-p80 protects against Schistosoma mansoni infection in the mouse model to levels previously attainable only by the irradiated cercarial vaccine. Parasitol Res 2009; 105:1767-77; PMID:19809833; http://dx.doi.org/10.1007/s00436-009-1646-z
18. Ahmad G, Torben W, Zhang W, Wyatt M, Siddiqui AA. Sm-p80-based DNA vaccine formulation induces potent protective immunity against Schistosoma mansoni. Parasite Immunol 2009; 31:156-61; PMID:19222788; http://dx.doi.org/10. 1111/j.1365-3024.2008.01091.x
19. Ahmad G, Zhang W, Torben W, Damian RT, Wolf RF, White GL, Chavez-Suarez M, Kennedy RC, Siddiqui AA. Protective and antifecundity effects of Sm-p80-based DNA vaccine formulation against Schistosoma mansoni in a nonhuman primate model. Vaccine 2009; 27:2830-7; PMID:19366570; http://dx.doi.org/10.1016/j. vaccine.2009.02.096
20. Ahmad G, Zhang W, Torben W, Noor Z, Siddiqui AA. Protective effects of Sm-p80 in the presence of resiquimod as an adjuvant against challenge infection with Schistosoma mansoni in mice. Int J Infect Dis 2010; 14:e781-7; PMID:20630783; http://dx.doi.org/10.1016/j.ijid.2010.02.2266
21. Ahmad G, Zhang W, Torben W, Ahrorov A, Damian RT, Wolf RF, White GL, Carey DW, Mwinzi PN, Ganley-Leal L, et al. Preclinical prophylactic efficacy testing of Sm-p80-based vaccine in a nonhuman primate model of Schistosoma mansoni infection and immunoglobulin G and E responses to Sm-p80 in human serum samples from an area where schistosomiasis is endemic. J Infect Dis 2011; 204:1437-49; PMID:21921206; http://dx.doi.org/10.1093/infdis/jir545
22. El Ridi R, Tallima H. Schistosoma mansoni ex vivo lung-stage larvae excretory-secretory antigens as vaccine candidates against schistosomiasis. Vaccine 2009; 27:666-73; PMID:19056448; http://dx.doi.org/10.1016/j.vaccine. 2008.11.039
23. El Ridi R, Tallima H, Mahana N, Dalton JP. Innate immunogenicity and in vitro protective potential of Schistosoma mansoni lung schistosomula excretory - secretory candidate vaccine antigens. Microbes Infect 2010; 12:700-9; PMID:20452455; http://dx.doi.org/10.1016/j.micinf.2010.04.012
24. Hota-Mitchell S, Siddiqui AA, Dekaban GA, Smith J, Tognon C, Podesta RB. Protection against Schistosoma mansoni infection with a recombinant baculovirus-expressed subunit of calpain. Vaccine 1997; 15:1631-40; PMID:9364694; http://dx.doi.org/10.1016/S0264-410X(97)00081-9
25. Hota-Mitchell S, Clarke MW, Podesta RB, Dekaban GA. Recombinant vaccinia viruses and gene gun vectors expressing the large subunit of Schistosoma mansoni calpain used in a murine immunization-challenge model. Vaccine 1999; 17:1338-54; PMID:10195769; http://dx.doi.org/10.1016/S0264-410X(98)00391-0
26. Siddiqui AA, Phillips T, Charest H, Podesta RB, Quinlin ML, Pinkston JR, Lloyd JD, Pompa J, Villalovos RM, Paz M. Enhancement of Sm-p80 (large subunit of calpain) induced protective immunity against Schistosoma mansoni through codelivery of interleukin-2 and interleukin-12 in a DNA vaccine formulation. Vaccine 2003; 21:2882-9; PMID:12798631; http://dx.doi.org/10.1016/S0264-410X(03) 00159-2
27. Siddiqui AA, Phillips T, Charest H, Podesta RB, Quinlin ML, Pinkston JR, Lloyd JD, Paz M, Villalovos RM, Pompa J. Induction of protective immunity against Schistosoma mansoni via DNA priming and boosting with the large subunit of calpain (Sm-p80): adjuvant effects of granulocyte-macrophage colony-stimulating factor and interleukin-4. Infect Immun 2003; 71:3844-51; PMID:12819068; http://dx.doi.org/10.1128/IAI.71.7.3844-3851.2003
28. Siddiqui AA, Pinkston JR, Quinlin ML, Kavikondala V, Rewers-Felkins KA, Phillips T, Pompa J. Characterization of protective immunity induced against Schistosoma mansoni via DNA priming with the large subunit of calpain (Sm-p80) in the presence of genetic adjuvants. Parasite 2005; 12:3-8; PMID:15828575; http://dx.doi.org/10.1051/parasite/2005121003
29. Zhang W, Ahmad G, Torben W, Noor Z, Le L, Damian RT, Wolf RF, White GL, Chavez-Suarez M, Podesta RB, et al. Sm-p80-based DNA vaccine provides baboons with levels of protection against Schistosoma mansoni infection comparable to those achieved by the irradiated cercarial vaccine. J Infect Dis 2010; 201:1105-12; PMID:20187746; http://dx.doi.org/10.1086/651147
30. Zhang W, Ahmad G, Torben W, Siddiqui AA. Sm-p80-based DNA vaccine made in a human use approved vector VR1020 protects against challenge infection with Schistosoma mansoni in mouse. Parasite Immunol 2010; 32:252-8; PMID:20398225; http://dx.doi.org/10.1111/j.1365-3024.2009.01181.x
31. Zhang W, Ahmad G, Torben W, Siddiqui AA. Schistosoma mansoni antigen Sm-p80: Prophylactic efficacy of a vaccine formulated in human approved plasmid vector and adjuvant (VR 1020 and alum). Acta Trop 2011; 118:142-51; PMID:21334302; http://dx.doi.org/10.1016/j.actatropica.2011.01.010
32. Ohta N, Kumagai T, Maruyama H, Yoshida A, He Y, Zhang R. Research on calpain of Schistosoma japonicum as a vaccine candidate. Parasitol Int 2004; 53:175-81; PMID:15081949; http://dx.doi.org/10.1016/j.parint.2004.01.007
33. Zhang R, Yoshida A, Kumagai T, Kawaguchi H, Maruyama H, Suzuki T, Itoh M, El-Malky M, Ohta N. Vaccination with calpain induces a Th1-biased protective immune response against Schistosoma japonicum. Infect Immun 2001; 69:386-91; PMID:11119528; http://dx.doi.org/10.1128/IAI.69.1.386-391.2001
34. Siddiqui AA, Siddiqui BA, Ganley-Leal L. Schistosomiasis vaccines. Hum Vaccin 2011; 7:1192-7; PMID:22048120; http://dx.doi.org/10.4161/hv.7.11.17017
35. Kumagai T, Maruyama H, Hato M, Ohmae H, Osada Y, Kanazawa T, Ohta N. Schistosoma japonicum: localization of calpain in the penetration glands and secretions of cercariae. Exp Parasitol 2005; 109:53-7; PMID:15639140; http://dx.doi.org/10.1016/j.exppara.2004.11.001
36. Mourão MM, Dinguirard N, Franco GR, Yoshino TP. Phenotypic screen of early-developing larvae of the blood fluke, schistosoma mansoni, using RNA interference. PLoS Negl Trop Dis 2009; 3:e502; PMID:19668375; http://dx.doi.org/10.1371/journal.pntd.0000502
37. Braschi S, Wilson RA. Proteins exposed at the adult schistosome surface revealed by biotinylation. Mol Cell Proteomics 2006; 5:347-56; PMID:16269422; http://dx.doi.org/10.1074/mcp.M500287-MCP200
38. Siddiqui AA, Pinkston JR, Quinlin ML, Saeed Q, White GL, Shearer MH, Kennedy RC. Characterization of the immune response to DNA vaccination strategies for schistosomiasis candidate antigen, Sm-p80 in the baboon. Vaccine 2005; 23:1451-6; PMID:15670880; http://dx.doi.org/10.1016/j.vaccine.2004.09.018
39. Torben W, Ahmad G, Zhang W, Siddiqui AA. Role of antibodies in Sm-p80-mediated protection against Schistosoma mansoni challenge infection in murine and nonhuman primate models. Vaccine 2011; 29:2262-71; PMID:21277404; http://dx.doi.org/10.1016/j.vaccine.2011.01.040
40. Torben W, Ahmad G, Zhang W, Nash S, Le L, Karmakar S, Siddiqui AA. Role of antibody dependent cell mediated cytotoxicity (ADCC) in Sm-p80-mediated protection against Schistosoma mansoni. Vaccine 2012; 30:6753-8; PMID:23000221; http://dx.doi.org/10.1016/j.vaccine.2012.09.026
41. Arnon R, Tarrab-Hazdai R, Steward M. A mimotope peptide-based vaccine against Schistosoma mansoni: synthesis and characterization. Immunology 2000; 101:555-62; PMID:11122460; http://dx.doi.org/10.1046/j.1365-2567.2000.00139.x
42. Deng J, Gold D, LoVerde PT, Fishelson Z. Inhibition of the complement membrane attack complex by Schistosoma mansoni paramyosin. Infect Immun 2003; 71:6402-10; PMID:14573661; http://dx.doi.org/10.1128/IAI.71.11.6402-6410.2003
43. De Brito T, Hoshino-Shimizu S, da Silva LC, Kanamura H, Costa CM, Pinto PS. Immunopathology of experimental schistosome (S. Mansoni) egg granulomas in mice - possible defence mechanisms mediated by local immune complexes. J Pathol 1983; 140:17-28; PMID:6343568; http://dx.doi.org/10.1002/path.1711400104
44. La Flamme AC, MacDonald AS, Huxtable CR, Carroll M, Pearce EJ. Lack of C3 affects Th2 response development and the sequelae of chemotherapy in schistosomiasis. J Immunol 2003; 170:470-6; PMID:12496433
45. Buchman GW, Cohen ME, Xiao Y, Richardson-Harman N, Silvera P, DeTolla LJ, Davis HL, Eisenberg RJ, Cohen GH, Isaacs SN. A protein-based smallpox vaccine protects non-human primates from a lethal monkeypox virus challenge. Vaccine 2010; 28:6627-36; PMID:20659519; http://dx.doi.org/10.1016/j.vaccine.2010.07.030
46. Böttger EC, Metzger S, Bitter-Suermann D, Stevenson G, Kleindienst S, Burger R. Impaired humoral immune response in complement C3-deficient guinea pigs: absence of secondary antibody response. Eur J Immunol 1986; 16:1231-5; PMID:2945728; http://dx.doi.org/10.1002/eji.1830161008
47. Fischer MB, Ma M, Goerg S, Zhou X, Xia J, Finco O, Han S, Kelsoe G, Howard RG, Rothstein TL, et al. Regulation of the B cell response to T-dependent antigens by classical pathway complement. J Immunol 1996; 157:549-56; PMID:8752901
48. Purwar R, Bäumer W, Niebuhr M, Tschernig T, Kietzmann M, Werfel T. A protective role of complement component 3 in T cell-mediated skin inflammation. Exp Dermatol 2011; 20:709-14; PMID:21569105; http://dx.doi.org/10.1111/j.1600- 0625.2011.01295.x